Today's top gainers were led by Australia-based Gelteq, which develops a novel ingestible gel-based drug delivery platform; Adial Pharmaceuticals, which announced the acquisition of Azora Therapeutics as part of its pipeline expansion strategy; and Precigen, which is drawing renewed attention as its lead asset PAPZIMEOS gains commercial traction, among others.